XML 107 R88.htm IDEA: XBRL DOCUMENT v3.25.1
Note 14 - Segment Data - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 240,978 $ 216,187 $ 219,080
Depreciation in cost of revenues 3,160 3,031 3,163
Amortization in cost of revenues 2,641 6,052 6,796
Non-cash GKE inventory step-up amortization 1,232 1,229 0
Other cost of revenues (b) [2] 83,075 72,625 75,428
Total segment cost of revenues 90,108 82,937 85,387
Gross Profit (c) [3] 150,870 133,250 133,693
Operating expense 134,534 405,325 130,373
Operating income 16,336 (272,075) 3,320
Nonoperating expense, net 10,375 3,573 3,709
Earnings before income taxes 5,961 (275,648) (389)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax [1],[4] 0 0 0
Depreciation in cost of revenues [4] 0 0 0
Amortization in cost of revenues [4] 0 0 0
Non-cash GKE inventory step-up amortization [4] 0 0  
Other cost of revenues (b) [2],[4] 10 77 40
Total segment cost of revenues [4] 10 77 40
Gross Profit (c) [3],[4] (10) (77) (40)
Sterilization and Disinfection Control [Member] | Operating Segments [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax [1],[5] 93,418 [6] 75,124 [7] 64,609
Depreciation in cost of revenues [5] 1,419 1,204 818
Amortization in cost of revenues [5] 503 266 0
Non-cash GKE inventory step-up amortization [5] 1,232 1,229  
Other cost of revenues (b) [2],[5] 25,604 19,123 17,271
Total segment cost of revenues [5] 28,758 21,822 18,089
Gross Profit (c) [3],[5] 64,660 53,302 46,520
Clinical Genomics [Member] | Operating Segments [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax [1] 47,081 52,588 62,299 [8]
Depreciation in cost of revenues 680 937 1,130
Amortization in cost of revenues 765 4,448 5,675
Non-cash GKE inventory step-up amortization 0 0  
Other cost of revenues (b) [2] 19,966 20,125 23,009
Total segment cost of revenues 21,411 25,510 29,814
Gross Profit (c) [3] 25,670 27,078 32,485
Biopharmaceutical Development [Member] | Operating Segments [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax [1] 48,730 40,712 47,365
Depreciation in cost of revenues 224 224 314
Amortization in cost of revenues 1,373 1,338 1,121
Non-cash GKE inventory step-up amortization 0 0  
Other cost of revenues (b) [2] 17,220 13,750 15,590
Total segment cost of revenues 18,817 15,312 17,025
Gross Profit (c) [3] 29,913 25,400 30,340
Calibration Solutions [Member] | Operating Segments [Member]      
Revenue from Contract with Customer, Excluding Assessed Tax [1] 51,749 47,763 44,807
Depreciation in cost of revenues 837 666 901
Amortization in cost of revenues 0 0 0
Non-cash GKE inventory step-up amortization 0 0  
Other cost of revenues (b) [2] 20,275 19,550 19,518
Total segment cost of revenues 21,112 20,216 20,419
Gross Profit (c) [3] $ 30,637 $ 27,547 $ 24,388
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation, amortization, and non-cash inventory step-up amortization expenses.
[3] Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.
[4] Unallocated corporate expenses and other business activities are reported within Corporate and Other. Certain depreciation expense classified reflected in Corporate and Other in fiscal years 2024 and 2023 has been recast to conform to current year presentation.
[5] Includes GKE results beginning upon acquisition in fiscal year 2024.
[6] Revenues of $24,815 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2025.
[7] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales made beginning from the acquisition date.
[8] Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.